GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Reshape Lifesciences Inc (STU:24O0) » Definitions » Capex-to-Operating-Income

Reshape Lifesciences (STU:24O0) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Reshape Lifesciences Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Reshape Lifesciences's Capital Expenditure for the three months ended in Mar. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was €-2.03 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Reshape Lifesciences Capex-to-Operating-Income Historical Data

The historical data trend for Reshape Lifesciences's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reshape Lifesciences Capex-to-Operating-Income Chart

Reshape Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Reshape Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Reshape Lifesciences's Capex-to-Operating-Income

For the Medical Devices subindustry, Reshape Lifesciences's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reshape Lifesciences's Capex-to-Operating-Income Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Reshape Lifesciences's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Reshape Lifesciences's Capex-to-Operating-Income falls into.



Reshape Lifesciences Capex-to-Operating-Income Calculation

Reshape Lifesciences's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.039) / -13.424
=N/A

Reshape Lifesciences's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -2.033
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reshape Lifesciences  (STU:24O0) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Reshape Lifesciences Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Reshape Lifesciences's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Reshape Lifesciences (STU:24O0) Business Description

Traded in Other Exchanges
Address
1001 Calle Amanecer, San Clemente, CA, USA, 92673
Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

Reshape Lifesciences (STU:24O0) Headlines

No Headlines